Literature DB >> 17007840

Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes.

Sebastiano A Musumeci1, Giuseppe Calabrese, Carmela M Bonaccorso, Simona D'Antoni, Judith R Brouwer, Cathy E Bakker, Maurizio Elia, Raffaele Ferri, David L Nelson, Ben A Oostra, Maria Vincenza Catania.   

Abstract

The Fmr1 knockout (KO) mouse is characterized by an increased audiogenic seizure (AGS) susceptibility and is considered a good animal model for epilepsy and seizures in the human fragile-X (FRAX) syndrome. Here, we tested the hypothesis that the reintroduction of the FMR1 gene is able to revert the AGS susceptibility characterizing Fmr1 KO mice. To this aim, two groups of Fmr1 KO transgenic mice, which have additional copies of the human FMR1 gene (YAC) or FMR1 cDNA (G6) were used. AGS susceptibility of these mice was examined and compared to that of Fmr1 KO, wild type, and wild-type animals in whom the FMR1gene was also introduced (over-expressed). Mice were tested at different ages because AGS susceptibility is age dependent. The intensity of response was scored and the results were analyzed by means of 2-way analysis of variance to evaluate the effects of age and genetic condition. We found that AGS susceptibility rescue is complete in the G6 mice and partial in YAC mice. Our data indicate that the introduction of the human FMR1 gene in Fmr1 KO mice is able to revert the Fmr1 KO epileptic phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17007840     DOI: 10.1016/j.expneurol.2006.08.007

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  30 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

Review 2.  Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders.

Authors:  Greg C Carlson
Journal:  Pharmacol Biochem Behav       Date:  2011-02-16       Impact factor: 3.533

3.  The role of GABAergic system in neurodevelopmental disorders: a focus on autism and epilepsy.

Authors:  Paola Sgadò; Mark Dunleavy; Sacha Genovesi; Giovanni Provenzano; Yuri Bozzi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-09

Review 4.  Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.

Authors:  D Sinclair; B Oranje; K A Razak; S J Siegel; S Schmid
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 5.  Emerging pharmacotherapies for neurodevelopmental disorders.

Authors:  Daniel Z Wetmore; Craig C Garner
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

6.  Abnormal development of auditory responses in the inferior colliculus of a mouse model of Fragile X Syndrome.

Authors:  Anna O Nguyen; Devin K Binder; Iryna M Ethell; Khaleel A Razak
Journal:  J Neurophysiol       Date:  2020-04-22       Impact factor: 2.714

7.  Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.

Authors:  Jonathan W Lovelace; Teresa H Wen; Sarah Reinhard; Mike S Hsu; Harpreet Sidhu; Iryna M Ethell; Devin K Binder; Khaleel A Razak
Journal:  Neurobiol Dis       Date:  2016-02-02       Impact factor: 5.996

Review 8.  Animal and model systems for studying cystic fibrosis.

Authors:  Bradley H Rosen; Marc Chanson; Lara R Gawenis; Jinghua Liu; Aderonke Sofoluwe; Alice Zoso; John F Engelhardt
Journal:  J Cyst Fibros       Date:  2017-09-19       Impact factor: 5.482

9.  mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome.

Authors:  Rocco G Gogliotti; Rebecca K Senter; Jerri M Rook; Ayan Ghoshal; Rocio Zamorano; Chrysa Malosh; Shaun R Stauffer; Thomas M Bridges; Jose M Bartolome; J Scott Daniels; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn; Colleen M Niswender
Journal:  Hum Mol Genet       Date:  2016-03-02       Impact factor: 6.150

10.  Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome.

Authors:  Z Zeier; A Kumar; K Bodhinathan; J A Feller; T C Foster; D C Bloom
Journal:  Gene Ther       Date:  2009-07-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.